AU2001231531A1 - Follicle stimulating hormones - Google Patents
Follicle stimulating hormonesInfo
- Publication number
- AU2001231531A1 AU2001231531A1 AU2001231531A AU3153101A AU2001231531A1 AU 2001231531 A1 AU2001231531 A1 AU 2001231531A1 AU 2001231531 A AU2001231531 A AU 2001231531A AU 3153101 A AU3153101 A AU 3153101A AU 2001231531 A1 AU2001231531 A1 AU 2001231531A1
- Authority
- AU
- Australia
- Prior art keywords
- follicle stimulating
- stimulating hormones
- hormones
- follicle
- stimulating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 229940088597 hormone Drugs 0.000 title 1
- 239000005556 hormone Substances 0.000 title 1
- 230000004936 stimulating effect Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Endocrinology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Reproductive Health (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200000220 | 2000-02-11 | ||
| DKPA200000220 | 2000-02-11 | ||
| DKPA200001092 | 2000-07-14 | ||
| DKPA200001092 | 2000-07-14 | ||
| PCT/DK2001/000090 WO2001058493A1 (en) | 2000-02-11 | 2001-02-09 | Conjugates of follicle stimulating hormones |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2001231531A1 true AU2001231531A1 (en) | 2001-08-20 |
Family
ID=26068766
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2001231531A Abandoned AU2001231531A1 (en) | 2000-02-11 | 2001-02-09 | Follicle stimulating hormones |
Country Status (2)
| Country | Link |
|---|---|
| AU (1) | AU2001231531A1 (en) |
| WO (1) | WO2001058493A1 (en) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7173003B2 (en) | 2001-10-10 | 2007-02-06 | Neose Technologies, Inc. | Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF |
| US7157277B2 (en) | 2001-11-28 | 2007-01-02 | Neose Technologies, Inc. | Factor VIII remodeling and glycoconjugation of Factor VIII |
| US7214660B2 (en) | 2001-10-10 | 2007-05-08 | Neose Technologies, Inc. | Erythropoietin: remodeling and glycoconjugation of erythropoietin |
| WO2004050679A2 (en) * | 2001-10-22 | 2004-06-17 | Applied Research Systems Ars Holding N.V. | Mutant glycoproteins |
| MEP38608A (en) * | 2001-10-22 | 2011-02-10 | Merck Serono Sa | Gonadotrophins for folliculogenesis |
| US7553930B2 (en) | 2003-01-06 | 2009-06-30 | Xencor, Inc. | BAFF variants and methods thereof |
| KR20060003862A (en) | 2003-03-14 | 2006-01-11 | 네오스 테크놀로지스, 인크. | Branched water-soluble polymers and their eonjugates |
| SG155777A1 (en) | 2003-04-09 | 2009-10-29 | Neose Technologies Inc | Glycopegylation methods and proteins/peptides produced by the methods |
| US8791070B2 (en) | 2003-04-09 | 2014-07-29 | Novo Nordisk A/S | Glycopegylated factor IX |
| US9005625B2 (en) | 2003-07-25 | 2015-04-14 | Novo Nordisk A/S | Antibody toxin conjugates |
| UA88879C2 (en) * | 2003-09-02 | 2009-12-10 | Эплайд Рисерч Системз Эрс Холдинг Н.В. | Fsh glycosylation mutant |
| US20080305992A1 (en) | 2003-11-24 | 2008-12-11 | Neose Technologies, Inc. | Glycopegylated erythropoietin |
| US8633157B2 (en) | 2003-11-24 | 2014-01-21 | Novo Nordisk A/S | Glycopegylated erythropoietin |
| US20060040856A1 (en) | 2003-12-03 | 2006-02-23 | Neose Technologies, Inc. | Glycopegylated factor IX |
| ES2528739T3 (en) * | 2003-12-24 | 2015-02-12 | Glycofi, Inc. | Methods to eliminate mannosyl phosphorylation of glucans in glycoprotein production |
| US8361961B2 (en) | 2004-01-08 | 2013-01-29 | Biogenerix Ag | O-linked glycosylation of peptides |
| US20080300173A1 (en) | 2004-07-13 | 2008-12-04 | Defrees Shawn | Branched Peg Remodeling and Glycosylation of Glucagon-Like Peptides-1 [Glp-1] |
| WO2006031811A2 (en) | 2004-09-10 | 2006-03-23 | Neose Technologies, Inc. | Glycopegylated interferon alpha |
| ES2572779T3 (en) | 2004-10-29 | 2016-06-02 | Ratiopharm Gmbh | Remodeling and glucopegilation of Fibroblast Growth Factor (FGF) |
| WO2006074467A2 (en) | 2005-01-10 | 2006-07-13 | Neose Technologies, Inc. | Glycopegylated granulocyte colony stimulating factor |
| EP1871795A4 (en) | 2005-04-08 | 2010-03-31 | Biogenerix Ag | Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants |
| JP5216580B2 (en) | 2005-05-25 | 2013-06-19 | ノヴォ ノルディスク アー／エス | Glycopegylated factor IX |
| US20070105755A1 (en) | 2005-10-26 | 2007-05-10 | Neose Technologies, Inc. | One pot desialylation and glycopegylation of therapeutic peptides |
| EP2390263A1 (en) | 2005-08-26 | 2011-11-30 | Ares Trading S.A. | Process for the preparation of glycosylated interferon beta |
| EA014585B1 (en) | 2005-09-14 | 2010-12-30 | Арес Трейдинг С.А. | Method for the determination of poloxamers |
| US20090048440A1 (en) | 2005-11-03 | 2009-02-19 | Neose Technologies, Inc. | Nucleotide Sugar Purification Using Membranes |
| JP5199112B2 (en) * | 2005-12-09 | 2013-05-15 | アレス トレーディング ソシエテ アノニム | Method for purifying FSH or FSH variants |
| EP1976872B1 (en) * | 2005-12-22 | 2015-06-17 | Merck Serono SA | Fsh mutants |
| CA2633844A1 (en) * | 2006-01-17 | 2007-07-26 | Laboratoires Serono S.A. | Novel fsh glycosylation variant d3n |
| US20080280818A1 (en) | 2006-07-21 | 2008-11-13 | Neose Technologies, Inc. | Glycosylation of peptides via o-linked glycosylation sequences |
| US8969532B2 (en) | 2006-10-03 | 2015-03-03 | Novo Nordisk A/S | Methods for the purification of polypeptide conjugates comprising polyalkylene oxide using hydrophobic interaction chromatography |
| ES2406267T3 (en) | 2007-04-03 | 2013-06-06 | Biogenerix Ag | Treatment methods using glycopegylated G-CSF |
| JP5876649B2 (en) | 2007-06-12 | 2016-03-02 | ラツィオファルム ゲーエムベーハーｒａｔｉｏｐｈａｒｍ ＧｍｂＨ | Improved process for producing nucleotide sugars |
| EP2492280A1 (en) * | 2007-06-28 | 2012-08-29 | BioGeneriX AG | FSH producing cell clone |
| US8207112B2 (en) | 2007-08-29 | 2012-06-26 | Biogenerix Ag | Liquid formulation of G-CSF conjugate |
| ATE523209T1 (en) | 2008-02-08 | 2011-09-15 | Biogenerix Ag | LIQUID FORMULATION OF FSH |
| US20130189239A1 (en) | 2008-02-27 | 2013-07-25 | Novo Nordisk A/S | Conjugated Factor VIII Molecules |
| DK2414380T3 (en) | 2009-04-01 | 2015-10-19 | Ratiopharm Gmbh | Process for the purification of recombinant fsh |
| EP2325194A1 (en) | 2009-11-24 | 2011-05-25 | Glycotope GmbH | Process for the purification of glycoproteins |
| AU2012286048A1 (en) | 2011-07-18 | 2014-02-20 | Arts Biologics A/S | Long acting luteinizing hormone (LH) compound |
| WO2013167750A2 (en) | 2012-05-11 | 2013-11-14 | Prorec Bio Ab | Method for diagnosis and treatment of prolactin associated disorders |
| ES2837111T3 (en) * | 2015-04-24 | 2021-06-29 | Ferring Bv | Gonadotropin production procedure |
| KR101947340B1 (en) * | 2017-05-05 | 2019-02-12 | 주식회사 유비프로틴 | A method for extending half-life of FSH alpha |
| KR101947341B1 (en) * | 2017-05-05 | 2019-02-12 | 주식회사 유비프로틴 | A method for extending half-life of FSH beta |
| CL2018001347A1 (en) * | 2018-05-18 | 2019-03-15 | Centro De Biotecnologia Y Biomedicina Spa 94% | Recombinant bovine stimulating follicle hormone, a composition that comprises it and a method to induce superovulation and synchronization of heat in cattle using said hormone |
| KR20210083174A (en) * | 2019-12-26 | 2021-07-06 | 주식회사 엘지화학 | Method for Purifying Follicle stimulating hormone |
| CN114213523A (en) * | 2021-11-15 | 2022-03-22 | 广州源博医药科技有限公司 | High glycosylation modified sequence for recombinant protein, recombinant porcine follicle-stimulating hormone and application thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4904584A (en) * | 1987-12-23 | 1990-02-27 | Genetics Institute, Inc. | Site-specific homogeneous modification of polypeptides |
| US5218092A (en) * | 1988-09-29 | 1993-06-08 | Kyowa Hakko Kogyo Co., Ltd. | Modified granulocyte-colony stimulating factor polypeptide with added carbohydrate chains |
| ZA987497B (en) * | 1997-09-08 | 1999-02-23 | Akzo Nobel Nv | Expression of gonadotropins in dictyostelium |
-
2001
- 2001-02-09 AU AU2001231531A patent/AU2001231531A1/en not_active Abandoned
- 2001-02-09 WO PCT/DK2001/000090 patent/WO2001058493A1/en active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| WO2001058493A1 (en) | 2001-08-16 |
| WO2001058493A8 (en) | 2001-11-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2001231531A1 (en) | Follicle stimulating hormones | |
| AU2002230860A1 (en) | Skin desinfectant applicator | |
| AU2002214471A1 (en) | Map-aided positioning | |
| AU2001255522A1 (en) | Mri-resistant implantable device | |
| AU2001275822A1 (en) | Multiple-legged walking apparatus | |
| AU2001259702A1 (en) | Tissue regrafting | |
| AU2001233208A1 (en) | Human sulfatases | |
| AU2001272974A1 (en) | Human receptors | |
| AU2001283344A1 (en) | Dermatological formulation | |
| AU2001286061A1 (en) | Applicator | |
| AU2002227925A1 (en) | Human beta-defensin-3 | |
| AU2001282521A1 (en) | OCT preparations | |
| AUPR099200A0 (en) | New formulation | |
| AU2000274825A1 (en) | Cosmetic method | |
| AU2000238755A1 (en) | Dermatological compounds | |
| AU148865S (en) | Applicator | |
| AU2001292893A1 (en) | Applicator device | |
| AU2000273752A1 (en) | Cosmetic method | |
| GB0003296D0 (en) | Applicator | |
| AU2002349266A1 (en) | Applicator | |
| CA96239S (en) | Applicator | |
| AU2001252017A1 (en) | Electro-medical device | |
| AU4782800A (en) | Cosmetic | |
| AU2000245494A1 (en) | Handbag | |
| AUPQ964700A0 (en) | Applicator |